SVANasdaqPharmaceutical PreparationsFiscal year ends December 31
SINOVAC BIOTECH LTD
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 5, 2026
$6.47+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- 850.08%
Sinovac Biotech statistics
Financials through Dec 31, 2025, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Sinovac Biotech | Industry median |
|---|---|---|
| Market Cap | $464.94M | $166.30M |
| Enterprise Value | -$3.55B | $88.19M |
| PS Ratio | 1.20 | 3.65 |
| PB Ratio | 0.10 | 2.03 |
| P/TBV Ratio | 0.11 | 2.29 |
Enterprise value
| Measure | Sinovac Biotech | Industry median |
|---|---|---|
| EV / Sales | -9.19 | 2.51 |
Income (trailing twelve months)
| Measure | Sinovac Biotech | Industry median |
|---|---|---|
| Revenue | $386.01M | $58.34M |
| Gross Profit | $261.98M | $105.94M |
| Operating Income | -$490.13M | -$21.40M |
| Pretax Income | -$262.10M | -$14.34M |
| EBITDA | -$490.13M | -$16.91M |
| EPS (Diluted) | -$0.83 | -$0.83 |
Margins
| Measure | Sinovac Biotech | Industry median |
|---|---|---|
| Gross Margin | 67.9% | 52.9% |
| Operating Margin | -127.0% | -44.0% |
| Pretax Margin | -67.9% | -13.3% |
| EBITDA Margin | -127.0% | -30.2% |
| FCF Margin | -145.4% | -9.27% |
Returns
| Measure | Sinovac Biotech | Industry median |
|---|---|---|
| Return on Capital Employed (ROCE) | -7.00% | -38.1% |
Growth
| Measure | Sinovac Biotech | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 6.82% | 5.96% |
| EPS Growth (YoY) | -165.4% | -26.2% |
| Revenue Growth (3Y CAGR) | -36.0% | 2.25% |
| Revenue Growth (5Y CAGR) | -5.44% | 6.48% |
Balance sheet
| Measure | Sinovac Biotech | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $5.97B | $61.43M |
| Net Cash (Debt) | $5.97B | $15.35M |
| Net Cash Per Share | $83.10 | $0.66 |
| Equity (Book Value) | $4.44B | $49.09M |
| Book Value Per Share | $61.77 | $1.37 |
| Tangible Book Value | $4.35B | $23.52M |
| Working Capital | $5.52B | $76.81M |
Financial position
| Measure | Sinovac Biotech | Industry median |
|---|---|---|
| Current Ratio | 4.59 | 3.34 |
| Quick Ratio | 4.06 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Sinovac Biotech | Industry median |
|---|---|---|
| Operating Cash Flow | -$512.18M | -$12.35M |
| Capital Expenditures | -$48.92M | -$1.08M |
| Free Cash Flow | -$561.10M | -$20.22M |
| FCF Per Share | -$7.81 | -$0.42 |
Efficiency
| Measure | Sinovac Biotech | Industry median |
|---|---|---|
| Asset Turnover | 0.04 | 0.39 |
| Inventory Turnover | 1.30 | 2.70 |
| Revenue Per Employee | $148.35K | $404.87K |
| Employee Count | 2,602 | 74 |
Dividends and yields
| Measure | Sinovac Biotech | Industry median |
|---|---|---|
| FCF Yield | -120.7% | -8.72% |
| Dividend Yield | 850.1% | 1.82% |
| Buyback Yield | 0.00% | -0.59% |
| Shareholder Yield | 850.1% | 0.00% |
| Dividend Per Share | $55.00 | $0.83 |
| Years of Dividend Growth | 0 | 0 |
Shares
| Measure | Sinovac Biotech | Industry median |
|---|---|---|
| Shares Outstanding | 71,860,700 | 58,127,000 |
| Shares Change (YoY) | 0.00% | 10.9% |
| Float | 24,614,900 | 49,136,700 |
| Shares Held by Insiders | 65.7% | 11.6% |
Taxes
| Measure | Sinovac Biotech | Industry median |
|---|---|---|
| Income Tax | -$63.27M | $79.87K |
Scores
| Measure | Sinovac Biotech | Industry median |
|---|---|---|
| Altman Z-Score | 1.22 | -0.22 |
Calculated by StockData from Sinovac Biotech's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.